Skip to main content

Research Repository

Advanced Search

Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England

Bromilow, Tom; Holmes, Hayden; Coote, Laura; Woods, Sam; Pink, Joshua

Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England Thumbnail


Authors

Tom Bromilow

Hayden Holmes

Laura Coote

Sam Woods



Abstract

Background: An economic model was developed with guidance from the National Institute for Health and Care Excellence (NICE) ‘Managing Common Infections’ (MCI) Committee to evaluate the cost effectiveness of different antibiotic treatment sequences for treating Clostridioides difficile infection (CDI) in England. Methods: The model consisted of a 90-day decision tree followed by a lifetime cohort Markov model. Efficacy data were taken from a network meta-analysis and published literature, while cost, utility and mortality data were taken from published literature. A treatment sequence was defined as a first-line intervention or a different second-line intervention, and used constant third- and fourth-line interventions. The possible first- and second-line interventions were vancomycin, metronidazole, teicoplanin and fidaxomicin (standard and extended regimens). Total costs and quality-adjusted life-years (QALYs) were calculated and were used to run a fully incremental cost-effectiveness analysis. Threshold analysis was conducted around pricing. Results: Sequences including teicoplanin, fidaxomicin (extended regimen) and second-line metronidazole were excluded based on recommendations from the committee. The final pairwise comparison was between first-line vancomycin and second-line fidaxomicin (VAN-FID), and the reverse (FID-VAN). The incremental cost-effectiveness ratio for FID-VAN compared with VAN-FID was £156,000 per QALY gained, and FID-VAN had a 0.2% likelihood of being cost effective at a £20,000 threshold. Conclusion: First-line vancomycin and second-line fidaxomicin was the most cost-effective treatment sequence at the NICE threshold for treating CDI in England. The main limitation of this study was that the initial cure and recurrence rates of each intervention were applied constantly across each line of treatment and each round of recurrence.

Citation

Bromilow, T., Holmes, H., Coote, L., Woods, S., & Pink, J. (2023). Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England. PharmacoEconomics - Open, 7(5), 739-750. https://doi.org/10.1007/s41669-023-00420-3

Journal Article Type Article
Acceptance Date May 3, 2023
Online Publication Date Jun 12, 2023
Publication Date Sep 1, 2023
Deposit Date Aug 29, 2023
Publicly Available Date Aug 31, 2023
Journal PharmacoEconomics - Open
Print ISSN 2509-4262
Electronic ISSN 2509-4254
Publisher Springer
Peer Reviewed Peer Reviewed
Volume 7
Issue 5
Pages 739-750
DOI https://doi.org/10.1007/s41669-023-00420-3
Keywords Pharmacology (medical); Health Policy; Pharmacology

Files




You might also like



Downloadable Citations